Anastomotic biliary strictures (ABSs) occur in up to 15% of patients after liver transplantation (LT). The aim of this study was to compare the efficacy and safety of self-expandable metal stents (SEMS) versus multiple plastic stents (MPS). Databases were searched through April 2017. The outcome measures were technical success, stricture resolution, recurrence and complications. We synthesized the findings descriptively and performed a meta-analysis. Three randomized controlled trials and one retrospective cohort study were identified, including 179 MPS and 119 SEMS patients. Outcome data were pooled in a meta-analysis that showed an advantage of SEMS in terms of the number of ERCP procedures (mean difference: 1.69 ERCP; 95% CI, 1-2.39; P < 0.00001) and treatment days (mean difference: 40.2 days; 95% CI, 3.9-76.4; P = 0.03), with no differences in terms of ABS resolution or recurrence. Fourteen case series reported MPS outcomes and fifteen reported SEMS outcomes, including 647 and 419 patients, respectively. Based on low-quality evidence, we cannot draw any reliable conclusions on the superiority of MPS or SEMS strategies. Even though shorter treatment times and fewer ERCP procedures support the use of SEMS, whether one technique has well-defined advantages over the other remains unclear. Transplant International 2018; 31: 131-151 
Introduction
Despite advances in surgical techniques, organ selection, preservation and immunosuppression, biliary tract complications are the most common complications after liver transplantation (LT), with major impacts on patient and graft survival [1, 2] . Anastomotic biliary strictures (ABSs) occur in up to 15% of patients, mainly within the first year after transplantation [1, [3] [4] [5] [6] . Risk factors for ABS are related to both donor and recipient characteristics (e.g. prolonged ischaemia time, the fibrotic healing process, a mismatch in size between the donor and recipient bile ducts), tension at the anastomosis, the use of electrocauterization, bile leak and infection [2, 3, [7] [8] [9] [10] . The typical presentation involves elevated liver enzymes, obstructive jaundice and cholangitis. Endoscopic treatment is the first-line therapy in patients with duct-to-duct biliary anastomosis [6, [11] [12] [13] [14] [15] .
No standard protocol has emerged for the endoscopic management of ABS. Analogous with the more frequent benign biliary stricture (i.e. postcholecystectomy), endoscopic therapy for ABS usually requires biliary sphincterotomy plus balloon dilatation (BD) and stent placement [16] [17] [18] . Multiple plastic stents (MPS) are usually kept in place until stricture resolution or for a period of 12 months [19] [20] [21] . An increasing number of stents are placed through the stricture and exchanged every 2-3 months to reduce the likelihood of stent blockage [16, 18, 22, 23] . The reported ABS resolution rate in the literature using the MPS method is between 85% and 97%, with large differences between strategies [11, 13, 24, 25] .
Self-expandable metal stents (SEMS), which are usually used in biliary and pancreatic malignancies, have gained popularity in recent years because they may offer the advantages of longer stent patency and a larger diameter, allowing faster benign stricture resolution and requiring reintervention less often compared with MPS [26, 27] . SEMS should be kept in place for a minimum of 3 months as a shorter stenting duration could result in slower ABS resolution [28] [29] [30] . However, a higher stent migration rate has been described for initial SEMS compared with MPS [24] . Furthermore, SEMS carry a low but significant risk of tissue ingrowth and stent impaction [31] .
The current evidence is insufficient to suggest a clear advantage of one strategy over the other in the management of ABS. In a recent large multicentre prospective study [32] , the resolution rates using SEMS in 42 post-LT ABS patients were 68% and 75% at 3 and 6 months, respectively. Two recent trials comparing SEMS and MPS in patients with ABS [33, 34] found that the resolution rates were similar with both stent protocols, suggesting that SEMS may be a cost-effective alternative to MPS.
The aim of this systematic review was to provide an exhaustive overview of the literature concerning the efficacy and safety of SEMS and MPS techniques in the management of ABS after LT.
Materials and methods
The methodological approach included development of the selection criteria, definition of the search strategies, assessment of study quality and extraction of relevant data. The PRISMA statements checklist for reporting a systematic review was followed [35] .
Study inclusion criteria
The study selection criteria were defined before data collection for proper identification of eligible studies for the analysis. All publications in which the primary objective was to describe the efficacy, safety, complications and/or long-term outcomes of endoscopic treatments for ABS in LT patients were retrieved and analysed.
Randomized controlled trials (RCT), cohort studies, case-control studies and case series including more than five patients were considered eligible for inclusion. No trial duration limitation was set. Case reports, review articles and conference abstracts were not considered.
By applying the PICO (Population, Intervention, Comparison, and Outcome) framework, we defined the following study selection criteria:
Populations/participants: Adult deceased donor LT patients with ABS after duct-to-duct reconstruction. ABS was defined as a dominant narrowing at the anastomotic site as demonstrated by cholangiography. Early ABS was defined as a stricture occurring less than 3 months after LT, and late ABS was defined as a stricture occurring 3 months or more after LT.
Studies on ABS treatment in paediatric patients or after living donor LT were excluded because these cases involve a reduced-size graft from either split-liver transplantation or a living donor that can be associated with different biliary complications and ABS management compared to adult LT patients receiving a whole graft from a deceased donor.
Interventions: Patients who received both primary and secondary treatments for ABS with either MPS or covered (partially or fully) SEMS were eligible. Primary treatment was defined as the first endoscopic intervention for ABS, and secondary treatment was defined as a salvage endoscopic procedure after primary treatment failure. Studies that included both primary and secondary SEMS patients were analysed within a Secondary subgroup.
Comparison: MPS and SEMS were compared. Outcome measures included:
previous stricture dilation during endoscopic retrograde cholangiopancreatography (ERCP). Stricture resolution: defined by easy passage of contrast through the anastomosis during ERCP at the end of endoscopic treatment and improvements in clinical and liver blood chemistry. Resolution is defined as no need for further interventions. Stricture recurrence: defined by cholangiographic evidence of ABS and the need for endoscopic, percutaneous or surgical treatment related to cholestasis during the follow-up period after initial resolution.
Complications: defined as any adverse effect related to ERCP or stenting procedures.
Studies that did not clearly report ABS outcomes separately from other types of strictures (i.e. chronic pancreatitis) or from other complications (i.e. leaks) were excluded. Studies that focused on patients with nonanastomotic biliary strictures, hepatic artery stenosis and/or thrombosis, and hepaticojejunostomy strictures or on therapy with a single PS or BD only were also excluded.
Literature search strategy
A literature search was performed in the following online databases: MEDLINE, EMBASE, Scopus, Cochrane database and ProQuest Dissertations and Thesis Database. To increase the probability of identifying all relevant articles, a specific research equation was formulated for each database using the following keywords: anastomotic biliary stricture or stenosis or pathologic constriction, biliary duct-to-duct anastomosis, endoscopic biliary stent, liver transplantation, adult deceased donor liver transplant, endoscopic cholangiography, endoscopic treatment or therapy, hepatic artery thrombosis and nonanastomotic biliary strictures. In addition, reference lists from eligible studies and relevant review articles were cross-checked to identify additional publications. No time or language limitation was applied. The literature was searched from inception to April 2017.
Article selection and quality assessment
The titles and abstracts of retrieved articles were independently screened for relevance by two reviewers (FL and NdeA). To enhance sensitivity, records were removed only if both reviewers excluded the record at the title screening level. All disagreements were resolved by discussion with a third reviewer (AM-P). Subsequently, both reviewers performed a full-text analysis of the selected articles. The two reviewers independently assessed the risk of bias using appropriate tools according to the study design. Briefly, the Cochrane criteria described in the Cochrane Handbook for Systematic Reviews of Interventions [36] were applied for RCTs, and the Newcastle-Ottawa Scale (NOS) [37] was used for nonrandomized studies. The NICE checklist (http://www.nice.org.uk/) [38] was used for the quality assessments of case series, which involves ratings on an 8-point scale regarding eight questions concerning the following aspects: setting (i.e. uni-/multicentric), hypothesis/objective, case definition, outcome definition, data collection, patient recruitment, results description and analysis. Additionally, the Grading of Recommendations Assessment Development and Evaluation (GRADE) system was used to grade the "body of evidence" arising from this review [39] . GRADE specifies four categories: high, moderate, low and very low. In the context of a meta-analysis, the quality of evidence reflects the confidence that the estimates of the effect are correct and surpass the individual study risk of bias by evaluating the following aspects: study design, imprecision, inconsistency, indirectness of the study results and publication bias.
Data extraction and data analysis
Data from the included studies were processed for qualitative and quantitative analyses. Outcome measures (percentages, mean/median values with standard deviations/ranges) were extracted for each treatment approach. Average technical success, ABS resolution and recurrence rates and various complication rates were calculated as weighted percentages (and ranges) of the values reported. Whenever a meta-analysis of pooled data was possible, the risk ratio (RR) and 95% CI were estimated using the Mantel-Haenszel method for binary outcome data. The mean differences and 95% CIs were estimated using inverse variance weighting for continuous data. Heterogeneity was assessed by the I 2 statistic, and values of 25%, 50% and 75% were considered low, moderate and high, respectively [36, 40] . Random-effects models were used for the pooled estimates of the mean differences. The pooled effect was considered significant at P < 0.05. The meta-analysis was performed using REV-MAN software (version 5.3; Cochrane Collaboration).
Results

Literature search and selection
All database searches were performed in April 2017. A total of 277 articles were retrieved from MEDLINE, 201
Transplant International 2018; 31: 131-151from Scopus and 306 from EMBASE. After title and abstract evaluations, 84 articles were retained, 30 of which were ultimately excluded because they were not pertinent to the review question or were conference abstracts. A total of 54 articles underwent full-text evaluations. Among them, 22 were excluded for the following reasons: no relevance to the review question (n = 11), review articles (n = 6) and case reports including less than 5 patients (n = 5). An additional article was retrieved from the reference cross-check. Finally, 33 articles published between 2003 and 2017 were selected and included in qualitative synthesis (Fig. 1) Table 2 ). BD before stent placement was performed in approximately two-thirds of the patients. In most case series, the stent exchange interval was 3 months and the mean number of ERCP procedures per patient ranged between 2.5 and 5.
Technical success: The technical success rate of MPS in the case series was between 91.6 and 100%.
Stricture resolution: The ABS resolution rate in the MPS case series was between 53.8 and 100%, and the mean stent duration was between 3.5 and 15.8 months.
Stricture recurrence: The ABS recurrence rate for the MPS case series was between 0 and 21% after widely variable follow-up periods.
Complications: There was an overall per-ERCP complication rate between 0 and 16.2% and a per-patient complication rate between 0% and 71% (Table 5) .
Self-expandable metal stents studies
Three RCTs and one cohort study included a total of 119 patients with SEMS aged between 48 and 57 years [26,27,33,34]. Technical success was 100%, the resolution rate was 86-100%, the recurrence rate was 15-30%, treatment duration was 4-6 months and the average number of ERCPs/patient was 2 (Table 3) . included SEMS as both primary and secondary treatments in a total of 304 patients with an age range of 49-59 years. The mean number of ERCP procedures per patient was between 2.7 and 3.7 (Table 3) .
Technical success: The technical success rates were 100% for the primary SEMS case series and 86-100% for the secondary SEMS case series.
Stricture resolution: The ABS resolution rate in the primary SEMS case series was 53.3-100%, with a mean stent duration between 2 and 6.8 months. In the secondary SEMS cases series, the rate was 50-100%, with a mean stent duration between 2 and 9.2 months.
Stricture recurrence: The overall ABS recurrence rate in the primary SEMS case series was 8.3-30.3%. In the secondary SEMS case series, the rate was 4.5-47.4%.
Complications: The per-patient complication rate in the primary SEMS case series was 10-46.7%. In the secondary SEMS cases series, the rate was 12.9-63.6% (Table 5) .
Meta-analysis of the RCTs and cohort study
Three RCTs [27,33,34] and one cohort study [26] were included in the meta-analysis for different outcomes.
Overall analysis: The pooled data from the three RCTs [27,33,34] and the cohort study [26] showed ABS resolution in 153 (91%) of 167 patients who received MPS and in 100 (92%) of 108 patients who received SEMS (RR: .89; 95% CI, 0.40-2.02; P = 0.79; heterogeneity I 2 = 0%) (Fig. 2) . The same studies showed recurrence in 16 (10.5%) of the 152 MPS patients and in 23 (23%) of the 100 SEMS patients (RR: .55; 95% CI, 0.22-1.38; P = 0.20; heterogeneity I 2 = 20%). The pooled data from the RCTs [27,34] and cohort study [26] found no differences in treatment duration (mean difference of 83.5 days; 95% CI, À4.1 to 171 days; P = 0.06; heterogeneity I 2 = 91% (Fig. 3) . The same studies found recurrence in 9/61 MPS patients (14.7%) and in 13/67 SEMS patients (19.4%) (RR: 0.88; 95% CI, .38-2.02; P = 0.76; heterogeneity I 2 = 9%). The pooled data from two Table 2 . Summary of patient characteristics and outcomes in studies and case series using MPS for ABS after LT †Relative to whole group of MPS patients (including other type of strictures). Table 3 . Summary of patient characteristics and outcomes in studies using SEMS for ABS after LT.
Author, year 
Management of recurrence
Treatments after recurrence are summarized in Table 4 . For the patients who previously underwent MPS placement, repeat ERCP was the most frequent treatment, followed by surgery and SEMS placement. For the patients who initially underwent SEMS placement, repeat SEMS or MPS placement was the most common treatment after recurrence, followed by surgical procedures. Overall, three patients [42,58] needed a second LT for ABS recurrence, including one after MPS therapy and two after SEMS therapy.
Quality assessments of the studies and case series
Most of the publications were case series without a control group. Only three RCTs were found. By applying the Cochrane criteria, the risk of bias was considered low in one study [34] and high in two studies [27, 33] . The quality of the retrospective cohort study [26] according to the NOS was 7/9, and the risk of bias was classified as low (Table S1 ). (Fig. S1) . Based on the GRADE concerning the quality of evidence for meta-analysis, one RCT had high-quality evidence [34] and three studies had moderate-quality evidence [26, 27, 33] .
Discussion
The present systematic review describes the outcomes of two endoscopic treatments for ABS in adult LT patients. The outcomes summarized in the present systematic review, which are based on low-quality evidence, do not allow the determination of any reliable conclusion regarding the superiority of one technique over another in terms of efficacy and safety. However, the data from the meta-analysis of the RCTs suggest advantages in Table 3 . Continued. †Values are relative to PCSEMS and two types of FCSEMS, respectively. ‡Relative to whole group of SEMS patients (including other type of strictures). §In 24/44 (54%), it was possible to directly set the SEMS in place at the 1st attempt, whereas in 20/44 (46%) PS were initially placed and then replaced 1 month later with SEMS. ¶Values in relation to patients without and with ABS recurrence, respectively.
terms of fewer ERCP procedures and shorter treatment durations in favour of SEMS. In recent years, the standard of care for symptomatic ABS has been ERCP as a first-line intervention, with MPS exchanged every 3 months over a 12-month period. There is no consensus on this treatment, with some authors supporting alternative timing while others preferring single stents or dilation alone to minimize complications [8, 13, 16, 43, 61] . However, this strategy requires repeated hospital admissions and endoscopic procedures and exposes patients to ERCP-associated morbidity [6, 62] . Kobayashi et al.
[63] demonstrated that endoscopic manoeuvring for biliary dilatation and stent placement following LT resulted in a higher risk of post-ERCP pancreatitis than the use of the same technique for the treatment of other types of biliary stricture. The potential benefit of a single covered selfexpandable metal stent is related to its relatively simple management compared with MPS. SEMS have larger diameters and are easily removed and can potentially limit costs by reducing the number of procedures needed to achieve ABS resolution [33] . However, Figure 2 Forest plots of the overall analysis. disadvantages such as a higher complication rate and migration may affect both patient tolerability and costs [27, 30, 64, 65] .
The technical success rates of both strategies are close to 100% in the studies and case series summarized in the present review. Relatively easy access to the stricture and stenting without any major complications with either technique represent ideal conditions for future RCTs.
For weeks. Such heterogeneity does not allow the determination of a reliable conclusion regarding the best timing strategy for MPS. The impact of closer surveillance or more frequent stent replacements should be investigated in a specifically designed RCT. Based on the limited available evidence, we recommend MPS replacement every 12 weeks with a monthly outpatient physical examination and blood test surveillance to detect early signs of complications. For the SEMS concerning primary treatment were analysed to deduce the best strategy to prevent complications. Again, the significant variability in timing (replacement between 2 and 6 months) prevents the determination of any conclusions. Interestingly, both major trials using FCSEMS [33] provided a reliable cost analysis of both strategies. They found that the SEMS strategy was more cost-effective than the MPS strategy. The cost of completing the protocol for ABS treatment (Australian $) was lower for SEMS compared with MPS: 10.830 versus $23.580 (P = 0.02). They also analysed the costs for any additional procedures required during follow-up and found that SEMS were still more cost-effective ($12.913 vs. $29.280), but without statistical significance (P = 0.08).
A recent randomized controlled trial of noninferiority studied SEMS versus MPS in benign biliary strictures of different aetiologies [27] . The study enrolled 112 patients stratified by stricture aetiology and conducted endoscopic reassessments for resolution every 3 months (MPS) or every 6 months (FCSEMS), and 65% of the patients had ABS after LT. As reported by this study, among the patients with benign biliary strictures, SEMS were not inferior to MPS in achieving stricture resolution after 12 months of treatment. In a particular subgroup of LT patients, the observed resolution rate after 12 months of stenting was noninferior (SEMS 91.7% vs. MPS 93.9%), but a higher recurrence rate was observed among those randomized to receive SEMS (15.2% vs. 3.3%) compared to those who received MPS. Even if these outcomes are consistent with the results of the literature summarized in the present review, we cannot draw any definitive conclusions from this trial because the enrolment criteria included benign biliary strictures of other aetiologies (i.e. chronic pancreatitis). Consequently, the study was not adequately powered to conduct subgroup analyses to compare the efficacy of SEMS vs. MPS relative to various aetiologies. Despite this limitation, among LT patients who achieved ABS resolution, the number of ERCP procedures required to achieve stricture resolution was significantly lower for those randomized to receive SEMS vs. MPS (mean, 2.2 vs. 3.1). The same trend towards fewer ERCP procedures per patient in SEMS patients was reported by Tal et al. [34] and was confirmed by the results of the meta-analysis. Another important element that can be argued from the study of Cot e et al. is that endoluminal migration of SEMS remains a relevant clinical issue. In this clinical trial, the observed migration rate was 43%, which is consistent with previous case series in which Tarantino et al. [30, 56] reported a migration rate greater than 40% for both primary and secondary treatments with SEMS. The overall migration rate of the summarized studies and case series included in this review represents a probable underestimation of this particular complication due to the retrospective design of most of the articles. Some reports suggest that patients treated with SEMS with some kind of inherent antimigration design (i.e. modified SEMS with a central waist and a long removal string) showed fewer complications [33,59,66]. Park et al. [65] showed that significantly less stent migration occurred among patients treated with SEMS anchored with a 5F double-pigtail plastic stent compared to a nonanchored group (6.3% vs. 41.2%).
Although the heterogeneity of the studies and case series does not allow any reliable comparison between SEMS and MPS patients, substantial qualitative differences in terms of the types of complications between the groups are not apparent (Table 5) reported a similar mean number of adverse events per ERCP procedure (although a subgroup analysis dedicated to post-LT ABS patients was not available) for both study arms (0.23 MPS vs. 0.36 SEMS; P = 0.31). Our systematic review attempted to summarize the current literature on the endoscopic treatment of ductto-duct ABS after LT. Although a considerable number of publications were retrieved overall, the total evidence is insufficient and is often underpowered to draw definitive conclusions. Moreover, heterogeneity was observed in endoscopic management across different studies and case series, indicating that caution is required when interpreting the results. Despite these limitations, the present systematic review and meta-analysis highlights the efficacy and safety of both strategies to achieve ABS resolution and manage biliary complications via minimally invasive methods. Future RCTs should aim to establish the best therapeutic strategy between SEMS and MPS to reduce the number of per-patient endoscopic procedures, decrease the complication rate and reduce costs.
Because of the low-quality evidence, we cannot draw any reliable conclusions on the superiority of MPS or SEMS strategies. Even though shorter treatment durations and fewer ERCP procedures advocate in favour of SEMS, whether one technique has clear advantages over the other remains unclear. This issue should be addressed in further adequately powered, randomized clinical trials.
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